GlassScriptPhysician profile
Joanna Yeh
NPI 1720249584
$875.51
in general payments reported to CMS, 2019-2025
14 companies · $83.61 in 2025
The $83.61 reported for 2025 was less than what a typical Pediatric Gastroenterology provider received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $347 · 2022: $6.87 · 2023: $169 · 2024: $269 · 2025: $83.61.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $514 · Education: $7.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $514.27 |
| Education | $7.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcresta Therapeutics, INC. | $170.68 | 2019-2024 | Relizorb |
| Abbvie INC. | $128.67 | 2019-2023 | Linzess |
| Mirum Pharmaceuticals, INC. | $110.97 | 2023-2025 | Livmarli |
| Intercept Pharmaceuticals, INC. | $109.81 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $71.13 | 2024-2025 | Eohilia, Gattex |
| Albireo Pharma, INC. | $69.35 | 2023-2024 | Bylvay |
| Qol Medical, LLC | $54.29 | 2024 | Sucraid |
| Nestle Healthcare Nutrition INC. | $34.23 | 2023 | |
| Kyowa Kirin, INC. | $27.99 | 2023 | |
| Celltrion USA INC. | $22.74 | 2024 | Zymfentra |
| Ironwood Pharmaceuticals, INC | $21.94 | 2023 | Linzess |
| Rhythm Pharmaceuticals, INC. | $20.67 | 2025 | Imcivree |
| Neurocrine Biosciences, INC. | $18.48 | 2024 | Ingrezza |
| Travere Therapeutics, INC. | $14.56 | 2022-2023 | Cholbam |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joanna Yeh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.